Algernon Pharmaceuticals Provides Reminder on Expiry Date of Accelerated Warrants
VANCOUVER, British Columbia, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to provide a reminder to the market that the common share purchase warrants of the Company that were issued on November 1, 2019 (the “November Warrants”), have had their expiry date accelerated to January 21, 2021.
The Company announces that as of today’s date, approximately 2M November Warrants remain unexercised of the approximately 6.5M that were outstanding, when they were accelerated on December 23, 2020, pursuant to the terms of the Indenture. Any remaining November Warrants not exercised by close of business January 21, 2021 will be accordingly cancelled.